Helix and AstraZeneca Sign Multi-Year Genomics Research Agreement
Genomics company Helix announced a multi-year agreement with AstraZeneca, granting the pharmaceutical firm access to Helix's genomics database for drug discovery and development.
San Mateo, Calif. – Helix, an enterprise genomics company, announced a multi-year agreement with AstraZeneca, the global biopharmaceutical company. The partnership will provide AstraZeneca with access to Helix's continuously growing genomics database to support drug discovery and development efforts.
While specific terms were not disclosed, the collaboration is expected to accelerate the identification and development of new therapies by leveraging comprehensive genomic data.
Helix provides genomics solutions for businesses and has a platform used in health and medical research.
AstraZeneca focuses on discovering, developing, and commercializing new medicines across several therapeutic areas worldwide.